ClinTec International, a global CRO with a presence in over 40 countries worldwide, announced its intention to formally open an office in Istanbul, Turkey. The office will not only provide ClinTec’s global team with access to a new patient population, but will also further consolidate the British CRO’s presence in the Middle East and North Africa (MENA) region. The office adds to the company’s current MENA region offices based in Cairo, Egypt, Dubai Health Care City, UAE, and Beirut, Lebanon.
Speaking at the announcement of ClinTec’s new office, the company’s founder and CEO, Dr Rabinder Buttar commented; “The launch of this new office in Turkey confirms ClinTec International’s reputation as a truly global provider of quality assured clinical research services. It also reflects the growing significance of Turkey- and the wider MENA region- to the global clinical research market. We are delighted to be at the forefront of developing expertise in Turkey and the MENA region as a whole.”
If you would like further information on ClinTec International, our new offices, or details of our training schemes, including the new MSc International Clinical Research and Technology please contact:
Bobby Bal, Senior Director, Corporate Development,
Glasgow, Scotland, UK.
Phone: +44 (0)141 226 1120
Fax: +44 (0)141 248 8993
Email : [email protected]www.clintec.com
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.